Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COSCIENS Biopharma ( (TSE:CSCI) ) has provided an update.
COSCIENS Biopharma Inc. reported a 17% increase in revenue and a 19% rise in gross profit for Q2 2025, alongside a 28% reduction in operating expenses compared to Q2 2024. The company has restructured its board and management, initiated a workforce reduction, and decided to delist from Nasdaq to focus on its core business and reduce costs, while maintaining its TSX listing.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life science company specializing in natural ingredients and pharmaceutical solutions. The company is focused on optimizing its base business, realigning its cost structure, and evaluating portfolio growth to maintain competitiveness in the biotechnology and pharmaceutical industry.
Average Trading Volume: 1,802
Technical Sentiment Signal: Sell
Current Market Cap: C$14.76M
For detailed information about CSCI stock, go to TipRanks’ Stock Analysis page.